Mainly engaged in the development and production of new pharmaceutical intermediates

lnvolved in anti-cancer, cardiovascular, mental diseases and other fields


Clopidogrel Bisulfate

Product Name:

Clopidogrel hydrogen sulfate PLAVIX;





SR-25990C, Plavix, Methyl(+)-(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3Chemicalbook,2-c]pyridine-5(4H)acetate,Hydrogen sulfate salt;methyl2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate sulfate;

(RS)-Clopidogrel bisulfate

Product Features

1. Cas No: 135046-48-9
2. Molecular formula: C16H16ClNO2S.H2O4S
3.Chemical Structure


4. Melting point : 184°C
5. Boiling point: 423.7ºC at 760 mmHg
6. Storage conditions: 2-8°C

Description: Clopidogrel hydrogen sulfate is a new type of antiplatelet aggregation drug similar to ticlopidine, which was successfully developed by Sanofi Saint Drabble company of France. It is suitable for the prevention and treatment of heart, brain and other arterial circulation disorders caused by high platelet aggregation, such as recent stroke, myocardial infarction and patients with confirmed peripheral arterial diseases. At present, it has been widely used in many countries, such as the United States, Europe and China. This product can inhibit platelet activation and platelet aggregation by inhibiting adenosine diphosphate (ADP) pathway. As it takes several days for clopidogrel bisulfate to reach the effective blood concentration, it is not suitable for emergency treatment. Platelet function returned to normal after 7-10 days of discontinuation.

Application: Clopidogrel bisulfate is used in the synthesis of clopidogrel derivatives as platelet aggregation inhibitors. Clopidogrel bisulfate was developed by Sanofi under the trade name of Plavix. It is one of the essential medicines designated by who. Clopidogrel is a platelet aggregation inhibitor. On November 17, 1997, the US Food and Drug Administration (FDA) approved Sanofi Aventis Plavix ("Plavix") for the treatment of myocardial infarction, post-stroke and confirmed peripheral arterial chemical Book disease (PAD). In 1999, the guidelines of American College of Cardiology and American Heart Association on AMI proposed that clopidogrel should replace ticlopidine because of its wide range of safety, and is recommended for patients with aspirin allergy or poor drug resistance. In October 2002, the American College of Cardiology and the American Heart Association (ACC / AHA) published revised guidelines for the combined use of clopidogrel and aspirin in the treatment of unstable angina or non-Q-wave myocardial infarction on the circulation.

product_detail (6)

We are Princechem Pharmaceutical manufacturer pass 20 years experience.  Types of chemical reactions in are etherification, ammoniation, chlorination, esterification, cyclization, hydrogenation and Grignard reaction, etc..Over the past 10 years, more than 400 catalog products were developed. In recent years, more than 40 kinds of key pharmaceutical intermediates have been developed, involving anti-cancer, cardiovascular, digestive system, mental diseases and other fields. It includes the key intermediates of API such as Quetiapine, Fluvaxamine, Erlotinib, Gefitinib, Sunitinib, Lapatinib, Rabeprazole and Lafutidine. For many years, we have been providing high quality pharmaceutical intermediates for many world-famous pharmaceutical companies.

HI-Tech Enterprise was honored to YPC in 2011. The company adheres to scientific and technological innovation and has more than 10 authorized invention patents.

YPC insists on using the international standard management systems to promote our managements and have established the systems of ISO9001:2000, ISO14001:2004 and OHS18001:1999. Over the past few years, it has passed on-site audits by more than 20 international and domestic pharmaceutical companies.

product_detail (1)
详情页Contact us

  • Previous:
  • Next:

  • Write your message here and send it to us